Figure 7.

17α-E2 treatment increases fetuin-A, a potent inhibitor of TGF-β1, in liver. A: liver fetuin-A protein at the conclusion of the 8-wk intervention (n = 12–17/group). B: representative immunoblots of liver fetuin-A and GAPDH at the conclusion of the 8-wk intervention. All data are shown as means ± SE and were analyzed by one-way ANOVA with Tukey’s post hoc testing. We did not indicate statistical differences between vehicle and 17α-E2 treatment groups (preventive and therapeutic), or between 17α-E2 treatment groups (preventive and therapeutic), for purposes of visual clarity. *P < 0.05, **P < 0.01. TGF-β1, transforming growth factor β1; 17α-E2, 17α-estradiol.